GO
Loading...

Big pharma tax attack

Tuesday, 29 Jul 2014 | 8:04 AM ET

Fundamentally, U.S.-based companies are at a disadvantage because of our tax code, says Barbara Ryan, FTI Consulting, sharing her thoughts on tax inversion among the big pharma space.